These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 31393377)
1. Expression of CD133 is associated with poor prognosis in stage II colorectal carcinoma. Park YY; An CH; Oh ST; Chang ED; Lee J Medicine (Baltimore); 2019 Aug; 98(32):e16709. PubMed ID: 31393377 [TBL] [Abstract][Full Text] [Related]
2. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer. Stanisavljević L; Myklebust MP; Leh S; Dahl O Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662 [TBL] [Abstract][Full Text] [Related]
3. Clinical significance of circulating tumor cells, including cancer stem-like cells, in peripheral blood for recurrence and prognosis in patients with Dukes' stage B and C colorectal cancer. Iinuma H; Watanabe T; Mimori K; Adachi M; Hayashi N; Tamura J; Matsuda K; Fukushima R; Okinaga K; Sasako M; Mori M J Clin Oncol; 2011 Apr; 29(12):1547-55. PubMed ID: 21422427 [TBL] [Abstract][Full Text] [Related]
4. Increased expression of CD133 is a strong predictor of poor outcome in stage I colorectal cancer patients. Reggiani Bonetti L; Migaldi M; Caredda E; Boninsegna A; Ponz De Leon M; Di Gregorio C; Barresi V; Scannone D; Danese S; Cittadini A; Sgambato A Scand J Gastroenterol; 2012 Oct; 47(10):1211-7. PubMed ID: 22856425 [TBL] [Abstract][Full Text] [Related]
5. CD133 expression is not an independent prognostic factor in stage II and III colorectal cancer but may predict the better outcome in patients with adjuvant therapy. Mia-Jan K; Jung SY; Kim IY; Oh SS; Choi E; Chang SJ; Kang TY; Cho MY BMC Cancer; 2013 Mar; 13():166. PubMed ID: 23537343 [TBL] [Abstract][Full Text] [Related]
6. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status. Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031 [TBL] [Abstract][Full Text] [Related]
7. CD133 expression correlates with clinicopathologic features and poor prognosis of colorectal cancer patients: An updated meta-analysis of 37 studies. Huang R; Mo D; Wu J; Ai H; Lu Y Medicine (Baltimore); 2018 Jun; 97(23):e10446. PubMed ID: 29879012 [TBL] [Abstract][Full Text] [Related]
8. Intravascular emboli is an independent risk factor for the prognosis of stage III colorectal cancer patients after radical surgery. Pei Q; Zhu H; Tan F; Yu N; Zhou Z; Zhou Y; Song X; Li Y; Tao Y; Zhang S; Li L; Li Q; Pei H Oncotarget; 2016 Aug; 7(35):57268-57276. PubMed ID: 27528226 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of CTCs and CSCs of tumor drainage vein blood in Dukes' stage B and C colorectal cancer patients. Shimada R; Iinuma H; Akahane T; Horiuchi A; Watanabe T Oncol Rep; 2012 Apr; 27(4):947-53. PubMed ID: 22267181 [TBL] [Abstract][Full Text] [Related]
10. High expression of CD133 - stem cell marker for prediction of clinically agressive type of colorectal cancer. Kostovski O; Antovic S; Trajkovski G; Kostovska I; Jovanovic R; Jankulovski N Pol Przegl Chir; 2020 Apr; 92(3):9-14. PubMed ID: 32759397 [TBL] [Abstract][Full Text] [Related]
11. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer. Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798 [TBL] [Abstract][Full Text] [Related]
12. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Takahashi S; Kamiyama T; Tomaru U; Ishizu A; Shida T; Osaka M; Sato Y; Saji Y; Ozaki M; Todo S Oncol Rep; 2010 Nov; 24(5):1201-12. PubMed ID: 20878111 [TBL] [Abstract][Full Text] [Related]
13. AC133 expression associated with poor prognosis in stage II colorectal cancer. Ying X; Wu J; Meng X; Zuo Y; Xia Q; Chen J; Feng Y; Liu R; Li L; Huang W Med Oncol; 2013 Mar; 30(1):356. PubMed ID: 23322518 [TBL] [Abstract][Full Text] [Related]
14. Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies. Tao Y; Li H; Huang R; Mo D; Zeng T; Fang M; Li M Cell Physiol Biochem; 2018; 46(4):1716-1726. PubMed ID: 29730663 [TBL] [Abstract][Full Text] [Related]
15. Clinicopathological significance and prognostic value of EphA3 and CD133 expression in colorectal carcinoma. Xi HQ; Zhao P J Clin Pathol; 2011 Jun; 64(6):498-503. PubMed ID: 21415057 [TBL] [Abstract][Full Text] [Related]
16. Exploring the clonal evolution of CD133/aldehyde-dehydrogenase-1 (ALDH1)-positive cancer stem-like cells from primary to recurrent high-grade serous ovarian cancer (HGSOC). A study of the Ovarian Cancer Therapy-Innovative Models Prolong Survival (OCTIPS) Consortium. Ruscito I; Cacsire Castillo-Tong D; Vergote I; Ignat I; Stanske M; Vanderstichele A; Ganapathi RN; Glajzer J; Kulbe H; Trillsch F; Mustea A; Kreuzinger C; Benedetti Panici P; Gourley C; Gabra H; Kessler M; Sehouli J; Darb-Esfahani S; Braicu EI Eur J Cancer; 2017 Jul; 79():214-225. PubMed ID: 28525846 [TBL] [Abstract][Full Text] [Related]
17. Do relevant markers of cancer stem cells CD133 and Nestin indicate a poor prognosis in glioma patients? A systematic review and meta-analysis. Wu B; Sun C; Feng F; Ge M; Xia L J Exp Clin Cancer Res; 2015 May; 34(1):44. PubMed ID: 25967234 [TBL] [Abstract][Full Text] [Related]
18. Combined prognostic value of the cancer stem cell markers CD47 and CD133 in esophageal squamous cell carcinoma. Wang JH; Huang ST; Zhang L; Liu ZG; Liang RX; Jiang SW; Jiang YN; Yu XJ; Jiang YC; Li XZ; Zhang PF; Wen ZS; Zheng M Cancer Med; 2019 Mar; 8(3):1315-1325. PubMed ID: 30741466 [TBL] [Abstract][Full Text] [Related]
19. Clinicopathological and prognostic significance of cancer stem cell markers CD44 and CD133 in patients with gastric cancer: A comprehensive meta-analysis with 4729 patients involved. Lu L; Wu M; Sun L; Li W; Fu W; Zhang X; Liu T Medicine (Baltimore); 2016 Oct; 95(42):e5163. PubMed ID: 27759647 [TBL] [Abstract][Full Text] [Related]
20. Augmented CD133 expression in distal margin correlates with poor prognosis in colorectal cancer. Pradhan T; Padmanabhan K; Prasad M; Chandramohan K; Nair SA J Cell Mol Med; 2019 Jun; 23(6):3984-3994. PubMed ID: 30950180 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]